



Mechanisms and Novel Therapeutic Approaches for Gynecologic Cancer

Guest Editor:

Dr. Naomi Nakayama

Department of General Medicine
and Community Health Science,
School of Medicine, Hyogo
Medical University, Hyogo 669-
2321, Japan

Deadline for manuscript
submissions:

closed (30 September 2021)

Message from the Guest Editor

Dear Colleagues,

The number of patients who suffer gynecologic cancer, such as ovarian cancer and endometrial cancer, has been increasing worldwide. A possible cause of the high lethality of gynecologic cancer includes the lack of early detection tools and effective therapeutic interventions. In this regard, basic research on their pathophysiology and novel molecular-based therapeutic strategies is urgently required.

In this background, there will be a Special Issue of Biomedicines entitled “Mechanisms and Novel Therapeutic Approaches for Gynecologic Cancer” which will focus on how basic research such as genomics, epigenomics, and proteomics as well as clinical research can contribute to the improvement of the mortality of the gynecologic cancer patients. We would like to welcome basic and clinical research which can show us the possibility of the wide variety of therapeutic approaches for gynecological cancer. In addition to original articles, review articles describing recent interesting topics regarding gynecologic cancer are also welcomed.

Dr. Naomi Nakayama

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI